Novorex develops therapeutics for cancer and central nervous system diseases through the development of new low-molecular drugs. Its drug development platform uses Fragment-based Drug Discovery (FBDD), which involves screening and optimizing small, low molecular-weight compounds known as fragments. The company was founded in 2020 and is based in Seongnam, South Korea.
Expert Collections containing Novorex
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Novorex is included in 1 Expert Collection, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Novorex Frequently Asked Questions (FAQ)
When was Novorex founded?
Novorex was founded in 2020.
Where is Novorex's headquarters?
Novorex's headquarters is located at 240 Pangyoyeok-ro, Bundang-gu, Seongnam.
What is Novorex's latest funding round?
Novorex's latest funding round is Series B.
How much did Novorex raise?
Novorex raised a total of $18.07M.
Who are the investors of Novorex?
Investors of Novorex include UTC Investment, Company K Partners, BNH Investment, Hana Ventures, QUAD Investment Management and 10 more.